Table 2.

Response during and after Therapy.^*

Response	Ledipasvir–Sofosbuvir for 12 Wk (N = 335)
	no. (%)
HCV RNA <LLOQ
During therapy period
At wk 2	272 (81)
At wk 4	331 (99)
After end of therapy
At wk 4	324 (97)
At wk 12†	322 (96)
Virologic breakthrough during treatment	2 (1)
Relapse in patients with HCV RNA <LLOQ at     end of therapy	10 (3)
Death	1 (<1)

^*LLOQ denotes lower limit of quantification (HCV RNA in serum, <25 IU per milliliter).

^†A sustained virologic response 12 weeks after the end of therapy was the primary end point.